Buy Liraglutide (GLP-1 Agonist) Research Peptide

Shop by goal

Popular compounds

BPC-157

Research resources

Compare pack sizes

Tap a pack to select it in the purchase panel above

Lab-direct quality — sealed 10-vial packs

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident. Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack in the strength your research needs.

Scientific Research Context

What the published literature on liraglutide examines at the molecular and cellular level. Findings about the compound in these studies are not claims about the supplied material.

Receptor potency and protraction

Native GLP-1 had an EC50 of 55 pM at the cloned human GLP-1 receptor in the assay used. Fatty-acid derivatives with chains of 12 or more carbons were markedly protracted compared with GLP-1, and the design aim was binding to serum albumin. [biochemical]

Structure-activity relationship

In the follow-up structure-activity work around liraglutide, the spacer region mainly affected potency, while fatty-acid length was the main determinant of protraction. [biochemical]

Islet-cell apoptosis in vitro

In primary neonatal rat islets, GLP-1 and liraglutide inhibited cytokine- and free-fatty-acid-induced apoptosis. The effect was blocked by exendin(9-39) and was cAMP- and PI3K-dependent. [in vitro]

Relation to semaglutide

Semaglutide was designed after liraglutide as a longer-acting analogue. It carries Aib8 and Arg34, is derivatised at Lys26, and bound the receptor with 0.38 nM affinity, three-fold lower than liraglutide, with higher albumin affinity. [biochemical]

Overview

In short: Liraglutide is a 31-residue acylated GLP-1 receptor agonist: native GLP-1(7-37) with one amino-acid substitution and a C16 fatty-acid side chain that binds serum albumin.

Key research facts

31-residue acylated GLP-1(7-37) analogue: Arg34 substitution and a C16 palmitoyl-γ-glutamate on Lys26

Fatty-acid chain designed for serum-albumin binding; fatty-acid length is the main determinant of protraction in the structure-activity work

GLP-1 receptor potency characterised in cloned-receptor assays

Cell-level work on cytokine- and fatty-acid-induced apoptosis in primary islets (cAMP and PI3K dependent)

Structural precursor of semaglutide, which was designed after it as a longer-acting analogue

These points summarise lab themes, not human outcomes.

Liraglutide keeps 30 of the 31 residues of GLP-1(7-37). Position 34 is arginine instead of lysine, and the remaining lysine at position 26 carries a palmitoyl group joined through a γ-glutamate spacer. The sequence is HAEGTFTSDVSSYLEGQAAK*EFIAWLVRGRG, where K* is the acylated lysine. The formula is C172H265N43O51 and the average mass is 3751.2 Da.

The molecular work on it is early: potency in cloned-receptor assays, protraction of fatty-acid derivatives, a structure-activity study of chain length, and cell-level work on islet apoptosis. The structure-activity work cited was done by the developer of the compound.

Liraglutide is also a medicine: it is approved in some jurisdictions under the originator's brand names. That is a fact about the subject compound. The material supplied here is laboratory research material, it is not one of those products, and published clinical findings are not summarised on this page because they describe other material and other protocols. No analytical report for the supplied material has been published yet, so this page quotes no purity figure.

Research class: GLP-1 receptor agonist; acylated GLP-1(7-37) analogue

Modification: Arg34; C16 palmitoyl-γ-glutamate on Lys26

Evidence base: Biochemical, in-vitro and structure-activity studies cited; clinical findings not summarised

Receptor Pharmacology

Liraglutide is a GLP-1 receptor agonist. Its fatty-acid side chain binds serum albumin, which is the design basis for its prolonged exposure compared with the native peptide.

Pathway Effect Why it matters GLP-1 receptor agonism Potent activity at the cloned human GLP-1 receptor The defining pharmacology of the compound, characterised in cell-based assays Albumin binding by the C16 chain Fatty-acid derivatives of 12 or more carbons were markedly protracted The design basis for a longer exposure than the native peptide Potency versus exposure Semaglutide's Aib8 substitution and longer chain bound the receptor with three-fold lower affinity than liraglutide and bound albumin more strongly Shows the trade-off between receptor potency and albumin binding within this series cAMP and PI3K signalling The anti-apoptotic effect in primary islets was blocked by exendin(9-39) and depended on cAMP and PI3K Shows receptor-mediated signalling downstream of the compound in cells

Deeper dive for scientific readers

The structure-activity work on fatty-acid derivatives of GLP-1 identified length as the main determinant of protraction and the spacer as the main determinant of potency. Liraglutide sits within that series. Semaglutide was later designed after it, with an Aib8 substitution and a longer chain, trading some receptor affinity for stronger albumin binding. This page describes molecular and cellular pharmacology only.

Common Questions People Are Asking

What is liraglutide?

Liraglutide is a 31-residue GLP-1 receptor agonist: native GLP-1(7-37) with an Arg34 substitution and a C16 palmitoyl-γ-glutamate on Lys26 that binds serum albumin. This page supplies it as laboratory research material only.

Is the material you supply the same as the approved medicine?

No. The compound is approved as a medicine in some jurisdictions under the originator's brand names. The research material supplied here is not one of those products, has no published analytical report yet, and is not for human or veterinary use.

Does published clinical research apply to this material?

No. Published clinical findings relate to the investigational and approved materials and the protocols used in those studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U research material, so they are not summarised on this page.

How does liraglutide differ from semaglutide?

Both are acylated GLP-1 analogues with Arg34 and a fatty acid on Lys26. Semaglutide has an additional Aib8 substitution and a longer chain, and was designed after liraglutide. In the discovery paper it bound the receptor with three-fold lower affinity than liraglutide and bound albumin more strongly.

Is it legal to buy liraglutide for research?

Liraglutide is a prescription medicine in some jurisdictions; the material supplied here is laboratory research material for in-vitro and preclinical use only, is not one of those medicines, and is not for human or veterinary use. Regulatory requirements vary by product, intended use and jurisdiction, and purchasers are responsible for ensuring that acquisition and use of research material complies with applicable requirements.

Is there a Certificate of Analysis for liraglutide?

Not yet. No independent analytical report has been published for this material, so no purity figure is quoted.

Where can I buy Liraglutide?

Right here - Liraglutide is supplied directly by New-U Research Compounds on this page, as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.

How much does Liraglutide cost?

Liraglutide pricing is shown live on this page, per pack size - 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, and shipping is free on orders over $350.

How do I buy Liraglutide?

Add the Liraglutide pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step.

What payment methods can I use to buy Liraglutide?

At checkout you can pay by card or crypto. New-U supports BTC and selected stablecoin and network-asset payments across Ethereum, Solana, TRON, Polygon, Base, BNB Chain and Linea. You choose your method after confirming your order.

How fast is shipping, and do you ship worldwide?

Yes - we ship worldwide in discreet, unmarked, tracked packaging; lyophilised peptides are stable through the tracked transit window. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Stability Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Notes Laboratory research material. No amount, schedule or administration guidance is published or recommended on this page.

Evidence Tier

Overall: Tier 1: Human clinical

The tier describes the published literature on the compound, not the supplied material. Liraglutide has an extensive published clinical record, which concerns the originator's products and trial protocols and is not summarised on this page because it does not describe the research material New-U supplies. The molecular pharmacology cited here comes from the developer. No analytical report for the supplied material has been published yet.

Databases & peer-reviewed sources

Last reviewed: 13 October 2026 · New-U Research Compounds

Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000. · 2000 · PMID: 10794683 · DOI: 10.1021/jm9909645

Madsen K, Knudsen LB, Agersoe H, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem 2007. · 2007 · PMID: 17975905 · DOI: 10.1021/jm070861j

Bregenholt S, Moldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005. · 2005 · PMID: 15796922 · DOI: 10.1016/j.bbrc.2005.03.013

Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem 2015. · 2015 · PMID: 26308095 · DOI: 10.1021/acs.jmedchem.5b00726

PubMed: peer-reviewed literature on Liraglutide

ClinicalTrials.gov: registered studies on Liraglutide

Liraglutide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

31-residue GLP-1(7-37) analogue with one substitution (Arg34)

C16 palmitoyl-γ-glutamate on Lys26, designed for albumin binding

Formula C172H265N43O51, average mass 3751.2 Da

Approved as a medicine in some jurisdictions under other brand names; this material is laboratory research material

No amount, schedule or administration guidance on this page

Supplied as 10-vial packs of 5, 10 or 30 mg vials; no analytical report published yet

Specifications

Sequence HAEGTFTSDVSSYLEGQAAK(γE-C16)EFIAWLVRGRG (31 residues) Molecular Formula C 172 H 265 N 43 O 51 Molecular Weight 3751.2 Da (average) Modification Arg34 substitution; C16 palmitoyl-γ-glutamate on Lys26 Form Lyophilised powder Pack 10 vials × 5 mg, 10 mg or 30 mg Analytical report None published yet Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light.

About Liraglutide: GLP-1 Receptor Agonist Research Guide

Liraglutide was developed by its originator, under the code NN2211, as part of a programme to make GLP-1 usable by attaching fatty acids that bind serum albumin. The 2000 paper in the Journal of Medicinal Chemistry reported that derivatives with chains of twelve or more carbons were markedly protracted, and the 2007 follow-up mapped how chain length, polarity and bulk set potency and protraction.

The compound is approved as a medicine in some jurisdictions. Those products and their trials are other people's material. Findings from them do not establish the safety, efficacy, intended use or equivalence of the research material supplied by New-U, and this page does not restate them.

New-U Research Compounds supplies liraglutide as a lyophilised research powder in sealed 10-vial packs of 5, 10 or 30 mg vials. No analytical report for the supplied material has been published yet, and this page makes no purity or certificate claim. It is for in-vitro and preclinical research only, is not a medicine, and nothing here is medical advice.

Knudsen et al., J Med Chem 2000 (PubMed 10794683)

Madsen et al., J Med Chem 2007 (PubMed 17975905)

Bregenholt et al., Biochem Biophys Res Commun 2005 (PubMed 15796922)

Lau et al., J Med Chem 2015 (PubMed 26308095)

Customer Reviews

No customer reviews yet - be the first to share your experience.

More in Metabolic Research

Metabolic Research Retatrutide Retatrutide (LY3437943) is an investigational triple GLP-1R / GIPR / GCGR agonist evaluated in registered clinical research. GLP1-RC-RT is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Retatrutide →

Metabolic Research Semaglutide Semaglutide is a long-acting GLP-1 receptor agonist characterised in published research, with 94% homology to native human GLP-1 and a C18 fatty-diacid albumin-binding modification. GLP1-RC-SM is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Semaglutide →

Metabolic Research Tirzepatide Tirzepatide is a dual GIP / GLP-1 receptor agonist characterised in published research, with imbalanced agonism favouring GIPR. GLP1-RC-TZ is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Tirzepatide →

Metabolic Research Cagrilintide Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research. Cagrilintide →

Metabolic Research Eloralintide Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology. Eloralintide →

Liraglutide vs related Metabolic Research compounds

Compound Price Purity spec COA Liraglutide from $278 Not published On request Retatrutide from $215 >99% HPLC 4 published batches Semaglutide from $158 >99% HPLC 1 published batch

Liraglutide vs Retatrutide - full comparison

Liraglutide vs Semaglutide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Liraglutide

Metabolic Research research compounds

Liraglutide research guide

Research this compound

Research guide Liraglutide research guide Liraglutide is a GLP-1 receptor agonist. Read the guide →

Compare Compare Liraglutide and Retatrutide Liraglutide vs Retatrutide: mechanism, receptor profile and specifications side by side. Compare →

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research